Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome

Pediatric Transplantation

Volumn 18, Issue 5, 2014, Pages

  Khandelwal, Priyanka ^a   Sinha, Aditi ^a   Hari, Pankaj ^a   Bansal, Virinder K ^a   Dinda, Amit K ^a   Bagga, Arvind ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

intravenous immunoglobulin; plasmapheresis; recurrent disease; rituximab

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; COMPLEMENT FACTOR H; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CHILD; FOLLOW UP; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRESCHOOL CHILD; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; BLOOD; HEMOLYTIC-UREMIC SYNDROME; IMMUNOLOGY; PROCEDURES; RECURRENT DISEASE; RENAL INSUFFICIENCY; TIME;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CHILD; COMPLEMENT FACTOR H; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PLASMA EXCHANGE; RECURRENCE; RENAL INSUFFICIENCY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904008508     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12273     Document Type: Article

References (15)

1. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005: 16: 555-563.
2. Hofer J, Janecke AR, Zimmerhackl LB, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013: 8: 407-415.
3. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010: 115: 379-387.
4. Blanc C, Roumenina LT, Ashraf Y, et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012: 189: 3528-3537.
5. Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010: 21: 2180-2187.
6. Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB,. Anti-factor H autoantibody-associated hemolytic uremic syndrome: Review of literature of the autoimmune form of HUS. Semin Thromb Hemost 2010: 36: 633-640.
7. Kwon T, Dragon-Durey MA, Macher MA, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008: 23: 2088-2090.
8. Le Quintrec M, Zuber J, Noel LH, et al. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009: 9: 1223-1229.
9. Waters AM, Pappworth I, Marchbank K, et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and CFHR3 deficiency and CFH variant G2850T. Am J Transplant 2010: 10: 168-172.
10. Sinha A, Gulati A, Saini S, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2013; doi: 10.1038/ki.2013.373.
11. Noris M, Remuzzi G,. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013: 22: 704-712.
12. Abarrategui-Garrido C, Martinez-Barricarte R, Lõpez-Trascasa M, de Cõrdoba SR, Sánchez-Corral P,. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009: 114: 4261-4271.
13. Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011: 7: 23-35.
14. Noone D, Waters A, Pluthero FG, et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 2014; 29: 841-851.
15. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012: 12: 2546-2553.